Welcome to our dedicated page for Casi Pharmaceuticals news (Ticker: CASI), a resource for investors and traders seeking the latest updates and insights on Casi Pharmaceuticals stock.
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) is a clinical-stage biopharmaceutical company whose news flow centers on the development and financing of CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases. Company announcements highlight clinical trial progress in immune thrombocytopenia (ITP) and renal allograft antibody-mediated rejection (AMR), as well as regulatory milestones in the United States and China.
Readers of CASI news can follow updates on its Phase 1 and Phase 1/2 studies, including dose-escalation designs, interim safety and efficacy data, and presentations at major medical meetings such as the American Society of Hematology (ASH) Annual Meeting. Press releases describe how CID-103 is being evaluated across multiple dose cohorts, report on platelet response outcomes in ITP, and discuss regulatory clearances such as FDA IND approvals and Chinese CTA approvals for AMR studies.
CASI’s news also covers corporate and capital markets developments, including convertible note financings, at-the-market equity raises, and Nasdaq listing compliance matters. The company has reported receiving a Nasdaq delisting determination related to market value of listed securities, its subsequent appeal, and an extension granted by a Nasdaq Hearings Panel to regain compliance. Governance changes, such as board appointments and the designation of a Non-Executive Chairman, are also detailed in recent releases.
In addition, CASI issues updates on its product portfolio and regulatory environment in China, including the expiration of the Import Drug Registration License for FOLOTYN and the impact on commercialization in that market. For investors and observers, the CASI news feed provides a consolidated view of clinical data releases, regulatory interactions, financing transactions, governance changes, and business updates that shape the company’s progress with CID-103 and related activities.
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman-based biopharmaceutical company, has reported a significant development in its ongoing dispute with Juventas. The company has filed a current report on Form 6-K with the SEC to disclose this material information. CASI, which focuses on developing and commercializing innovative therapeutics and pharmaceutical products, has made this filing to keep investors and stakeholders informed about the progress of the dispute. For detailed information, interested parties can access the full report through the SEC's EDGAR system using the provided link.
CASI Pharmaceuticals has appointed Dr. Daniel Lang as Chief Financial Officer and Senior Vice President, effective July 8, 2024. Dr. Lang brings over 30 years of experience, including roles as a physician-scientist, investor, and biotech executive. His background encompasses cardiology training at UCSF and investment roles at Farallon Capital and RS Investments Value Group. Most recently, he served as President of Athenex's cell therapy division. His appointment aims to leverage his diverse expertise for strategic shifts in CASI's anti-CD38 program focusing on antibody-mediated rejection and idiopathic thrombocytopenic purpura.
CASI Pharmaceuticals plans to submit an Investigational New Drug (IND) application to the FDA by the end of 2024 for CID-103, a monoclonal antibody for treating antibody-mediated rejection (AMR) in kidney transplant recipients. CID-103 has shown promising preclinical efficacy and safety. The company believes it has enough capital to complete a Phase II clinical trial for AMR, using proceeds from a private placement financing and existing funds.
Additionally, CASI received a non-binding proposal to acquire its entire China business for $40 million, which includes the assumption of up to $20 million in debt. The Board has formed a Special Committee to evaluate this proposal and other strategic alternatives. No final decisions have been made, and there is no assurance the transaction will proceed.
CASI Pharmaceuticals announced a $15 million private placement financing led by Venrock Healthcare Capital Partners and Foresite Capital, with participation from Panacea Venture and CEO Dr. Wei-Wu He. The financing involves selling 1,020,000 ordinary shares at $5.00 per share and pre-funded warrants for 1,980,000 shares at $4.9999 each. The transaction is expected to close in mid-July 2024, subject to customary conditions. Jefferies is acting as the placement agent. The company plans to file a registration statement with the SEC for the resale of the shares and pre-funded warrants.
On May 15, 2024, CASI Pharmaceuticals (NASDAQ: CASI) announced that the FDA has cleared their Investigational New Drug (IND) application for CID-103. This clearance supports a phase 1/2 study of CID-103 in adults with chronic Immune Thrombocytopenia (ITP), a serious autoimmune disorder. The IND application was submitted on April 12, 2024, and the FDA's approval letter was received on May 13, 2024.
CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody that has shown promising preclinical efficacy and safety profiles. Dr. Wei-Wu He, CEO of CASI, highlighted the potential of CID-103 to become a new therapeutic option for ITP, aiming to reduce the disease burden for patients.
CASI Pharmaceuticals reported its Q1 2024 financial results, revealing a significant 59% decrease in total revenue to $3.4 million, compared to $8.3 million in Q1 2023. This decline is primarily due to increased competition from generic melphalan products, inventory management strategies by EVOMELA®'s distributor, and restructuring of the sales force. Despite these challenges, CASI successfully launched its second commercial product, FOLOTYN®, and administered the first patient dose in China. The company also made progress in its pipeline, with promising Phase I results for BI-1206 in China and an IND submission for CID-103 for ITP in the US. Financial highlights include a net loss of $9.5 million and a decrease in cash and investments to $18.2 million as of March 31, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.